Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study.

Eur J Endocrinol · 2017 · PMC5425941 · PMID 28292927

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

In addition, there was an overall trend for dose reduction in patients receiving the highest daily doses at baseline (35 and 40 mg) so that dose levels were more in line with clinical practice in the rest of Europe.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.